...
首页> 外文期刊>Frontiers in Pediatrics >Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Pediatric Parotid Cancer
【24h】

Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Pediatric Parotid Cancer

机译:小儿腮腺癌预处理中性粒细胞对淋巴细胞比例的预后价值

获取原文
           

摘要

Objective: Our goal was to evaluate the prognostic significance of the neutrophil-to-lymphocyte ratio (NLR) in pediatric patients with parotid cancer. Materials and Methods: Pediatric patients with primary parotid cancer were retrospectively enrolled from several clinical centers. The associations between the clinical-pathologic variables and NLR and the prognostic significance of NLR for recurrence-free survival (RFS) and disease-specific survival (DSS) were analyzed. Results: A total of 123 patients were included. The mean NLR was 2.51 and ranged from 1.7 to 6.1. The tumor stage and disease grade were significantly related to NLR. In patients with NLR 2.51, the 10-year RFS rate was 97%, and in patients with NLR ≥2.51, the 10-year RFS rate was 84%; the difference was significant (p=0.016). In patients with NLR 2.51, the 10-year DSS rate was 98%, and in patients with NLR ≥2.51, the 10-year DSS rate was 83%; this difference was also significant (p=0.035). Further Cox model analysis confirmed the independence of NLR in predicting the RFS and DSS rates. Conclusions: NLR is significantly associated with prognosis in pediatric patients with parotid cancer.
机译:目的:我们的目标是评估腮腺癌中子粒细胞对淋巴细胞比(NLR)的预后意义(NLR)。材料和方法:患有原发性腮腺癌的儿科患者从几个临床中心回顾性。分析了临床病理变量和NLR之间的关联及NLR对复发存活(RFS)和疾病特异性存活(DSS)的预后意义。结果:共用123名患者。平均NLR为2.51,范围为1.7至6.1。肿瘤阶段和疾病等级与NLR显着相关。在NLR <2.51的患者中,10年的RFS率为97%,并且在NLR≥2.51的患者中,10年的RFS率为84%;差异很大(P = 0.016)。在NLR <2.51的患者中,10年的DSS率为98%,并且在NLR≥2.51的患者中,10年的DSS率为83%;这种差异也很显着(p = 0.035)。进一步的Cox模型分析证实了NLR在预测RFS和DSS率方面的独立性。结论:NLR在腮腺癌患者的预后显着相关。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号